annb0t
Top 20
MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection. (PRNewsfoto/Telix Pharmaceuticals Limited)
As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the ...
>>> Read more: First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the ...
>>> Read more: First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
